Top Markets
#1 DogBull DogBull +105.79%
#2 ADO Protocol ADO Protocol +50.39%
#3 Siacoin Siacoin +46.43%
#4 MarsCoin MarsCoin +38.80%
#5 The Bitcoin Bull The Bitcoin Bull +37.59%
#6 Glidr Glidr +24.49%
#7 Ontology Gas Ontology Gas +24.38%
#8 UnifAI Network UnifAI Network +21.47%
#9 Useless Coin Useless Coin +19.16%
#10 Falcon Finance Falcon Finance +17.48%
Coin of the day
DogBull DogBull
Settings
Language
ENGLISH
Currency
USD
Theme
Clover Biopharmaceuticals, Ltd. Clover Biopharmaceuticals, Ltd.

Clover Biopharmaceuticals, Ltd.

2197
Rank in Stocks #15713
Clover Biopharmaceuticals, Ltd. is a biotechnology enterprise focused on... Clover Biopharmaceuticals, Ltd. is a biotechnology enterprise focused on discovering, developing, and commercializing innovative vaccines and biological therapies. Their efforts target infectious diseases, various cancers, and autoimmune conditions. The company's pipeline features several key candidates: SCB-2019 (CpG 1018/Alum): A COVID-19 vaccine candidate currently advancing through Phase II/III clinical trials. SCB-313: A trimeric fusion protein aimed at treating severe intracavitary malignancies, including malignant ascites, malignant pleural effusions, and peritoneal carcinomatosis, addressing a significant global medical need. SCB-808: Undergoing pivotal Phase III clinical trials for the management of rheumatic disorders. SCB-420: An aflibercept biosimilar in preclinical development for ophthalmologic conditions like wet age-related macular degeneration. SCB-219: A novel TPOR agonist in preclinical stages for the treatment of chemotherapy-induced thrombocytopenia and immune thrombocytopenic purpura. Clover also holds a collaboration and supply agreement with Dynavax, which provides its CpG 1018 adjuvant for use in preclinical studies. The company was established in 2007 and is based in Shanghai, China.
Share Price
$0.25841098
Market Cap
$335.38M
Change (1 day)
-2.42%
Change (1 year)
73.70%
Country
CN
Trade Clover Biopharmaceuticals, Ltd. (2197)

Category

Healthcare
Revenue for Clover Biopharmaceuticals, Ltd. (2197)
Revenue in Sep 2026 TTM: 0
According to Clover Biopharmaceuticals, Ltd. latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Clover Biopharmaceuticals, Ltd. from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH